Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Liedtke

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Hematology. American Society of Hematology. Education Program|December 7, 2024
MGCS: where do we stand today?David Iberri, Michaela Liedtke
Best Practice & Research. Clinical Haematology|April 1, 2019
Therapy-related myeloid neoplasms after treatment for plasma-cell disordersAlfred Chung, Michaela Liedtke
Hematology. American Society of Hematology. Education Program|December 4, 2018
Antibody-based therapies in patients with acute lymphoblastic leukemiaShira Dinner, Michaela Liedtke
Blood|March 18, 2009
Therapeutic targeting of MLLMichaela Liedtke, Michael L Cleary
JACC. Cardiooncology|August 16, 2021
AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and ManagementRonald M Witteles, Michaela Liedtke
Expert Review of Hematology|November 19, 2010
Plasma cell leukemia: concepts and managementMichaela Liedtke, Bruno C Medeiros
Leukemia & Lymphoma|November 21, 2013
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemiaShira Dinner, Daniel Lee, Michaela Liedtke
Immunotherapy|May 17, 2019
B-cell maturation antigen directed monoclonal antibody therapies for multiple myelomaErik Eckhert, Rhonda Hewitt, Michaela Liedtke
Frontiers in Oncology|July 25, 2022
Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid NeoplasmFei Fei, Michaela Liedtke, Oscar Silva
Drug Design, Development and Therapy|August 9, 2018
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemiaIlana R Yurkiewicz, Lori Muffly, Michaela Liedtke
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Hematology. American Society of Hematology. Education Program|December 7, 2024
MGCS: where do we stand today?David Iberri, Michaela Liedtke
Best Practice & Research. Clinical Haematology|April 1, 2019
Therapy-related myeloid neoplasms after treatment for plasma-cell disordersAlfred Chung, Michaela Liedtke
Hematology. American Society of Hematology. Education Program|December 4, 2018
Antibody-based therapies in patients with acute lymphoblastic leukemiaShira Dinner, Michaela Liedtke
Blood|March 18, 2009
Therapeutic targeting of MLLMichaela Liedtke, Michael L Cleary
JACC. Cardiooncology|August 16, 2021
AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and ManagementRonald M Witteles, Michaela Liedtke
Expert Review of Hematology|November 19, 2010
Plasma cell leukemia: concepts and managementMichaela Liedtke, Bruno C Medeiros
Leukemia & Lymphoma|November 21, 2013
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemiaShira Dinner, Daniel Lee, Michaela Liedtke
Immunotherapy|May 17, 2019
B-cell maturation antigen directed monoclonal antibody therapies for multiple myelomaErik Eckhert, Rhonda Hewitt, Michaela Liedtke
Frontiers in Oncology|July 25, 2022
Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid NeoplasmFei Fei, Michaela Liedtke, Oscar Silva
Drug Design, Development and Therapy|August 9, 2018
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemiaIlana R Yurkiewicz, Lori Muffly, Michaela Liedtke
Pageof 11